Indoleamine 2,3-dioxygenase and immune changes under antidepressive treatment in major depression in females
Related Experiment Video
Updated: Apr 27, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Margarita Zoga1, Panagiotis Oulis2, Stylianos Chatzipanagiotou3
1Laboratory of Biopathology and Immunology, Athens University Medical School, Eginition Hospital, Athens, Greece.
Background/Aim:
Indoleamine 2, 3-dioxygenase (IDO) induction has been suggested as a mechanism by which immune activation affects tryptophan metabolism and serotonin synthesis in major depressive disorder (MDD). We investigated IDO and changes in inflammatory mediators in patients with MDD undergoing effective treatment.
Patients And Methods:
Forty female patients with MDD and 40 controls were recruited. Serum IDO was assessed by enzyme-linked immunosorbent assay (ELISA). We also determined tumor necrosis factor-α (TNFα), interferon-γ (IFNγ), C-reactive protein (CRP) and serotonin concentrations.
Results:
Patients' baseline concentrations of IDO and immune mediators were higher and serotonin concentrations were lower compared to controls. IDO and TNFα concentrations decreased under treatment and IDO changes were positively correlated with patient improvement. IFNγ and CRP concentrations remained unchanged. Serotonin concentration tended to increase.
Conclusion:
IDO might play an important role in the pathophysiology of MDD. Moreover, antidepressant therapy might reduce IDO production through an IFNγ-independent pathway. Finally, peripheral concentration of IDO assessed by ELISA might be a useful marker of MDD.
More Related Videos
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
06:15A Multiple Integrated Social Stress Model for Psychiatric Disorders in Female C57BL/6J Mice
Published on: July 15, 2025
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drugs Affecting Neurotransmitter Release or Uptake
Therapeutic Drug Monitoring: Affecting Factors
Drugs Affecting Neurotransmitter Synthesis